In this study published by the European Commission, Raphaël De Coninck, Pierre Régibeau, and Hans Zenger assess issues and solutions related to standard essential patents (SEPs) and the standardization process. It presents the costs and benefits of practical solutions to facilitate an efficient standardization process and SEP licensing. Concrete recommendations are offered on different issues such as FRAND terms, over-declaration, essentiality checks, conflict resolution process, and increasing transparency. To read more, click the link below.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...